RecruitingPhase 1NCT07824622

Study of Safety and PK of AZD0543 in Healthy Adults

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of AZD0543 in Healthy Adults

Sponsor

AstraZeneca

Enrollment

144 participants

Start Date

Aug 31, 2026

Study Type

INTERVENTIONAL

Conditions

Human Metapneumovirus Infection

Summary

The purpose of this study is to assess the safety and PK of AZD0543 compared to placebo in healthy adults 18 to 55 years of age. AZD0543 or placebo will be administered as single IM or IV dose. The study duration will be approximately 12 months for each participant following administration of IMP.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called AZD0543 and Placebo for people with human metapneumovirus infection. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAZD0543

Sterile solution for injection or infusion administered as a single IM or IV dose on Day 1.

OTHERPlacebo

Volume-matched 0.9% (w/v) sterile saline solution for injection or infusion administered as a single IM or IV dose on Day 1.

Locations(2)

Research Site

Los Alamitos, California, United States

Research Site

South Miami, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07824622